B cell homeostasis is regulated by multiple signaling processes, including nuclear factor-B (NF-B), BAFF-, and B cell receptor signaling. Conditional disruption of genes involved in these pathways has shed light on the mechanisms governing signaling from the cell surface to the nucleus. We describe a novel mouse strain that expresses solely and excessively a naturally occurring splice variant of CYLD ( CYLD ex7/8 mice), which is a deubiquitinating enzyme that is integral to NF-B signaling. This shorter CYLD protein lacks the TRAF2 and NEMO binding sites present in full-length CYLD. A dramatic expansion of mature B lymphocyte populations in all peripheral lymphoid organs occurs in this strain. The B lymphocytes themselves exhibit prolonged survival and manifest a variety of signaling disarrangements that do not occur in mice with a complete deletion of CYLD . Although both the full-length and the mutant CYLD are able to interact with Bcl-3, a predominant nuclear accumulation of Bcl-3 occurs in the CYLD mutant B cells. More dramatic, however, is the accumulation of the NF-B proteins p100 and RelB in CYLD ex7/8 B cells, which, presumably in combination with nuclear Bcl-3, results in increased levels of Bcl-2 expression. These fi ndings suggest that CYLD can both positively and negatively regulate signal transduction and homeostasis of B cells in vivo, depending on the expression of CYLD splice variants.
The tumor suppressor gene CYLD was identifi ed in patients with familial cylindromatosis, which is an autosomal dominant predisposition to multiple neoplasms of the skin appendages. The tumors are believed to arise from the eccrine or apocrine cells of the skin ( 1 ) . Approximately 70% of the cylindromas exhibit loss of heterozygosity on chromosome 16q containing the CYLD gene ( 2 -6 ) .
Sequence analysis of the CYLD gene predicts a protein with several functional domains, including three CAP-Gly domains and a deubiquitination domain at the C terminus ( 7 -9 ) . In vitro studies showed that CYLD contains binding sites for TRAF2 and NEMO ( 7 ) , and that the deubiquitinating activity of CYLD is directed to lysine 63 (K63) -linked ubiquitin (Ub) ( 7 ) . Linkage of Ub through K63 assembles a new molecular platform, allowing the recruitment of proteins involved in signal transduction ( 10 -12 ) , whereas Ub chains linked through K48 destine proteins for proteasomal degradation ( 13, 14 ) . Suppression of CYLD expression by RNA interference causes an increase in the activity of the transcription factor NF-B, which is activated by TNF ␣ signaling, thus inhibiting apoptosis ( 7, 8, 15 ) . The increase of NF-B activation in CYLD knockdown cells was attributed to defective removal of K63 Ub chains from TRAF2 and NF-B essential modulator (NEMO) by CYLD ( 7 -9 ) .
In a mechanistically analogous manner to its eff ect on TRAF2, CYLD was found to inhibit signaling from Tolllike receptor 2 (TLR2) by removing K63-linked Ub from TRAF6 and TRAF7 ( 16 ) . Interestingly, it was shown that after TLR2 activation, CYLD inhibits the phosphorylation of TRAF6 and TRAF7, which, in turn, suppresses MKK3 and MKK6, leading to reduced MAP kinase p38 phosphorylation ( 17 ) . In addition to p38 signaling, CYLD negatively regulates the stress-activating MAP kinase family, the JNK kinases. CYLD inactivation resulted in hyperactivation of JNK upon TNF ␣ , IL-1 ␤ , LPS, and anti-CD40 treatment ( 17 ) . This hyperactivation is believed to be a result of negatively regulating the activation of MKK7, which is the kinase responsible for JNK activation ( 17 ) .
To investigate the physiological role of CYLD in vivo, we generated mouse strains with targeted modifi cations in the CYLD gene. In addition to a complete knockout of CYLD , exon 7 of the CYLD gene was fl anked by loxP sites in a second mouse strain to result in conditional, excessive, and solitary expression of a shorter splice variant of the CYLD protein, hereafter termed sCYLD. The sCYLD protein is devoid of both TRAF2 and NEMO binding sites. In this article, we present data describing the profound alterations in the immune system of these mice ( CYLD ex7/8 ), which is characterized by lymphomegaly and splenomegaly and a striking increase in B cell numbers. Overexpression of sCYLD further bestows B lymphocytes with increased IgG1 production and enhances survival capabilities of the B cell.
RESULTS

Generation of CYLD ex7/8 mutant mice
CYLD mutant mice were generated applying standard genetargeting techniques in mouse embryonic stem cells (Fig.  S1 , available at http://www.jem.org/cgi/content/full/jem .20070318/DC1). Using Cre/loxP technology, three diff erent mouse strains were generated. The fi rst strain, CYLD neo , contains the neo resistance gene upstream of exon 7, decreasing transcription of CYLD (Fig. S1 ). The second strain, CYLD FL , harbors two loxP sites fl anking exon 7 of CYLD (Fig. S1 ). Finally, CYLD ex7/8 mice lacking exon 7 after Cre-mediated Lymphoid system defects in CYLD ex7/8 mice CYLD ex7/8 mice exhibited considerably larger spleens, LNs, and Peyer ' s patches ( Fig. 2 A and not depicted) . Careful microscopic examination revealed a disorganized structure of the spleen, where the distinct B cell and T cell zones of the follicle were not uniform as in WT spleens ( Fig. 2 B ) . Importantly, such abnormalities of the secondary immune organs were not reported in mice with complete inactivation of the CYLD gene ( 18 ) (unpublished data).
The CYLD ex7/8 mice displayed massively enlarged secondary lymphoid organs as early as 4 wk of age, whereas other tissues appeared normal (unpublished data). To investigate the mechanisms underlying these enlarged lymphoid organs, we examined lymphocyte populations of BM, spleen, LNs, and peritoneal cavity (PC). Analysis of B220 ϩ cells in the BM of CYLD ex7/8 mutant mice shows a small decrease in the percentage of the immature B lymphocyte compartments ( Fig.  3 A , top) . To analyze early B cell development, B220 ϩ IgM − cells were analyzed for the expression of the pro-B cell marker, c-Kit. We observed an increase in the pro-B cell fraction, indicating that deletion of the FL-CYLD leads to a partial block in early B cell diff erentiation ( Fig. 3 A , bottom) .
Strikingly, CYLD ex7/8 mice, but not heterozygous and control mice, demonstrate a dramatic accumulation of B cells in all secondary lymphoid organs tested ( Fig. 3 B and Table I ; not depicted for Peyer ' s patches). The proportion and absolute number of immature B cells was reduced in CYLD ex7/8 mice ( Fig. 3 C and Table I ), although they displayed significantly higher total B cell numbers ( Table I ) .
As seen in Fig. 3 D and Table I , the proportion, as well as the absolute number, of marginal zone (MZ; CD21 high CD23 low ) recombination through transient transfection of the targeted embryonic stem cells with a Cre-expressing plasmid (Fig. S1) . CYLD ex7/8 mice were born at the expected Mendelian frequencies and survived normally when housed under pathogenfree conditions.
Germline deletion of exon 7 should lead to splicing from exon 6 to 8 resulting in an out-of-frame translation of CYLD ( Fig. 1 A ) . RT-PCR was applied to cDNA from mouse embryonic fi broblasts (MEFs) of the indicated genotypes using primers located in exon 6 and 9 of the CYLD transcript to verify the absence of the WT allele in CYLD ex7 /8 MEFs. This analysis revealed an unexpected shorter amplifi ed product besides the expected band from the full-length transcript (FL-CYLD) in WT MEFs. This shorter product represents an alternative splice variant of CYLD lacking exons 7 and 8, termed sCYLD. CYLD ex7 /8 MEFs are devoid of the fulllength transcript, but express the sCYLD splice variant excessively ( Fig. 1 B ) . Using CYLD-specifi c antibodies, sCYLD protein could be detected in diff erent tissues and cells of WT animals ( Fig. 1 C ) . To investigate whether deletion of WT CYLD (FL-CYLD) in CYLD ex7/8 mice results in higher expression levels of sCYLD, protein extracts were prepared from purifi ed B cells of WT and CYLD ex7/8 mice, revealing high expression of sCYLD in CYLD ex7/8 cells compared with WT cells ( Fig. 1 D ) .
Previously, CYLD was identifi ed as a deubiquitinating enzyme, removing K63-conjugated Ub molecules from TRAF2, TRAF6, and NEMO ( 7 -9 ) . However, the putative TRAF2 and NEMO binding sites are absent in the sCYLD protein ( Fig. 1 E ) . To verify whether sCYLD is, indeed, unable to bind TRAF2, HeLa cells were transfected with expres sion plasmids encoding either FL-CYLD or sCYLD together with TRAF2-encoding or control plasmids. As shown in Fig. 1 F , FL-CYLD protein, but not sCYLD, coimmunoprecipitated with TRAF2, indicating that in contrast to FL-CYLD, sCYLD does not bind TRAF2. However, in an 8% SDS-PAGE, the diff erence in size between FL-CYLD and sCYLD could not be unambiguously demonstrated ( Fig. 1 F ) . In agreement, immunoprecipitated TRAF2 from extracts of CYLD ex7/8 MEFs was highly ubiquitinated compared with TRAF2 immunoprecipitated from WT cells ( Fig. 1 G ) . To investigate whether sCYLD is still able to function as a deubiquitinating enzyme, similar transfection experiments were applied to determine whether both CYLD proteins are capable of removing K63-conjugated Ub from Bcl-3, which is a novel substrate for CYLD ( 18 ) . The Bcl-3 binding site in CYLD is predicted to reside outside the area absent in sCYLD ( Fig. 1 E ) . We cotransfected HeLa cells with expression vectors encoding His-tagged Ub and Flagtagged Bcl-3, together with plasmids coding either for FL-CYLD, or for a catalytically inactive form of CYLD (C/S-CYLD) or for sCYLD. Fig. 1 B cell region located outside of the MOMA1 ϩ cells corresponding to the MZ B cells was larger in the mutant spleens compared with controls ( Fig. 3 E ) . Interestingly, the expansion of MZ and follicular B cells was accompanied by a decrease in the proportion and absolute number of B-1a (CD19 high CD5 ϩ CD23 Ϫ ) and B-1b (CD19 high CD5 Ϫ CD23 Ϫ ) B cells in the PC ( Fig. 3 F and Table I ). These results suggest that either overexpression of sCYLD or disruption of FL-CYLD is critical for regulating the maturation of BM B cells and the distribution of peripheral B cells.
To address whether these diff erences in the B cell compartment resulted from the overexpression of sCYLD, we analyzed another CYLD mutant strain, CYLD ko , in which the neomycin resistance gene was introduced into the fi rst coding exon of the CYLD gene, thus preventing its expression ( 18 ) . and follicular (CD21 in CD23 lo ) B cells were increased by twoto threefold in CYLD ex7/8 mice compared with WT mice. Interestingly, expression of CD21 and CD23 by B cells isolated from CYLD ex7/8 mice was elevated compared with control B cells ( Fig. 3 D ) . The latter was accompanied by an increase in cell size of the CYLD mutant B cells (unpublished data). To analyze the structure of MZ B cells, spleen sections from CYLD ex7/8 and littermate control mice were stained with anti-MOMA1 antibody, which binds to metallophilic macrophages, marking the border of the MZ. As shown in Fig. 3 E , MOMA1 ϩ cells can be detected in the spleens of CYLD ex7/8 ; however, the MZ appeared to be disordered and discontinuous compared with WT spleens. Furthermore, the amount of MOMA1 ϩ cells was increased without forming a closed ring around the follicle. Notably, the harbor a relatively high number of NP-specifi c precursor cells ( ‫ف‬ 1%) ( 19 ) . To test whether these fi ndings hold true for another TD antigen with lower precursor frequency, we immunized mice with KLH. CYLD ex7/8 mice developed signifi cantly higher levels of KLH-specifi c IgG1 antibodies after immunization compared with WT mice (Fig. S3 A, available at http://www.jem.org/cgi/content/full/jem.20070318/DC1). CYLD ex7/8 mice and littermate controls were also immunized with the T cell -independent (TI) antigen NP-Ficoll, resulting in similar levels of NP-specifi c IgM and IgG3 antibodies in CYLD ex7/8 and WT mice ( Fig. 4 C ) .
To examine whether the high IgG1 antibody levels observed in nonimmunized mice, as well as in the immunized mutant mice, were a consequence of increased antibody production by plasma cells or whether CYLD ex7/8 B cells switch more effi ciently to other antibody classes, B cells from WT and CYLD ex7/8 mice were isolated and, subsequently, incubated for 5 d ex vivo with optimal concentrations of LPS and IL-4. A higher proportion of CYLD mutant B cells switched to the IgG1 ϩ isotype compared with WT B cells (Fig. S3 B) . B cells in the Peyer ' s patches are constantly encountered by the gut fl ora, and therefore yield higher proportions of class-switched B cells. Peyer ' s patches from CYLD ex7/8 mice contain a threefold increased B cell population rich in IgG1-expressing B cells compared with WT mice ( Fig. 4 D ) . Additionally, these results were strengthened by an increased proportion of PNA ϩ Fas ϩ B cells in CYLD ex7/8 Peyer ' s patches, which is indicative of germinal center B cells ( Fig. 4 E ) . The hyper TD antigen-specifi c response observed in CYLD ex7/8 mice suggests that sCYLD is important for negatively regulating TD, but not TI, responses.
The B cell phenotype in CYLD ex7/8 mice is B cell intrinsic As all cells in CYLD ex7/8 mice lacked exon 7, it was unclear whether the defect in B cells was intrinsic to B cells or secondary (Fig. S2, B -D) . Moreover, B cell numbers in these mice were comparable to WT B cell numbers ( Table I ) . Thus, we conclude that the absence of the FL-CYLD, in tandem with the overexpression of sCYLD, is responsible for the increased proportion of B cells in the lymphoid organs of CYLD ex7/8 mice.
Skewed humoral immune response of CYLD ex7/8 mice To determine whether the expansion of B cells in CYLD ex7/8 mice affects the immune response, we evaluated serum antibody levels in CYLD ex7/8 and WT mice. The sera of CYLD ex7/8 mice contained signifi cantly lower IgM and IgG3 antibody titers compared with WT littermates, whereas all other tested antibody classes, including IgG1, IgG2a, IgG2b, and IgA, were elevated in CYLD ex7/8 mice ( Fig. 4 A ) . The latter antibody isotypes are more frequently secreted by classswitched B cells after encountering T cell -dependent (TD) antigens. Therefore, we next investigated TD antigen responses of CYLD ex7/8 B cells and control B cells. To this end, mice were challenged with nitrophenol-conjugated chicken ␥ -globulin (NP-CG) and immune responses were measured by ELISA. Upon in vivo challenge with NP-CG, CYLD ex7/8 mice developed signifi cantly lower antibody titers of both IgM and IgG3 isotypes, whereas secretion of NP-specifi c IgG1 and IgG2a antibodies was enhanced compared with WT mice ( Fig. 4 B ) . In addition, CYLD ex7/8 mice developed higher titers of NP-specifi c Ig antibodies, whereas the NPspecifi c Ig antibody levels were similar to the levels in WT mice ( Fig. 4 B , top) . Previously, it was shown that WT mice ( 4 ) 1.1 (0.1)
The mean size of lymphocyte populations was calculated based on their frequency as determined by fl ow cytometry ( Table I ). Finally, in both CD19-Cre / CYLD FL/FL and CYLD ex7/8 mice, the ratio of B-1 to B-2 B cells in the PC was inverted ( Fig. 5 E ) . Together, these data indicate that the B cell defects seen in the CYLD ex7/8 mice are cell autonomous.
Overexpression of sCYLD results in prolonged B cell survival
Bcl-2 transgenic mice exhibit enhanced B cell survival in vitro; this is associated with an increased size of secondary immune organs and B cell compartments in vivo ( 22 ) , which is similar to CYLD ex7/8 mice. To examine the survival capacities, B cells from CYLD ex7/8 and WT mice were cultured in enriched medium and monitored daily for survival by cell counting and FACS analysis. The CYLD mutant B cells exhibited prolonged survival compared with WT B cells ( Fig. 6 A , top) . assessed by quantitative real-time PCR. CYLD ex7/8 B cells express fi vefold more Bcl-2 mRNA compared with WT B cells ( Fig. 6 D ) . These results were further verifi ed at protein level by intracellular staining with Bcl-2 -specifi c antibody ( Fig. 6 D ) . In addition, we found that primary fi broblasts isolated from CYLD ex7/8 mutant mice are more resistant to TNF ␣ -induced apoptosis in the absence of protein synthesis ( Fig. 6 E ) . Therefore, it is tempting to speculate that the deletion of the FL-CYLD, concomitant with the overexpression of sCYLD, conveys increased resistance to apoptosis, leading to the enlarged B cell compartment in CYLD ex7/8 mice.
Next, we determined the responses of CYLD ex7/8 and WT B cells to activating stimuli by incubating CFSE-labeled B cell cultures with optimal concentrations of anti-IgM F(ab) Ј 2 and anti-CD40 antibodies, or with anti-RP105, LPS, or BAFF. As shown in Fig. 6 F , B cells from CYLD ex7/8 mice responded similarly to the diff erent stimuli compared with WT B cells. Although the addition of BAFF to culture medium resulted in a more activated status of the mutant B cells compared with the WT B cells ( Fig. 6 B ) , supplementing the culture with BAFF together with LPS failed to increase proliferation ( Fig. 6 F ) . Therefore, we conclude that sCYLD contributes to the survival capacity of B cells, but does not aff ect B cell proliferation.
Elevated expression of NF-B and TRAF proteins in resting CYLD ex7/8 B cells
Previously, CYLD was shown to act on diff erent proteins involved in the NF-B ( 7 -9 ) and mitogen-activated protein kinase (MAPK) signaling pathways ( 17, 24 ) . To study whether the enlargement of the B cell compartment in CYLD ex7/8 ( Fig.  6 A , bottom) . However, at all time points, CYLD ex7/8 B cells responded better to BAFF treatment compared with control B cells. Additionally, BAFF triggering of CYLD ex7/8 B cells resulted in the up-regulation of the activation markers CD40 and CD86, respectively, in comparison to WT B cells, whereas CpG treatment had similar eff ects on both B cell cultures ( Fig. 6 B ) . To investigate whether the increased numbers of mature B cells in CYLD ex7/8 mice was related to response to BAFF in vivo, CYLD mutant and control mice were treated with either TACI-or human-Ig as control. It was shown that TACI-Ig blocks BAFF signaling, and that this treatment resulted in a dramatic decrease in B cell numbers ( 23 ) . In treated WT mice, we detected a signifi cant decrease in the percentage of mature B cells in the mesenteric LN ( Fig.  6 C and Fig. S4 A, available at http://www.jem.org/cgi/ content/full/jem.20070318/DC1) and spleen (Fig. S4, B and C) . In contrast, the percentage of B cells in CYLD ex7/8 mice was hardly aff ected by the TACI-Ig treatment ( Fig. 6 C and Fig. S4 ). No diff erences in the total numbers of T cells in CYLD ex7/8 and WT mice were observed upon TACI treatment, showing that, indeed, TACI-Ig acts specifi cally on B lymphocytes (unpublished data).
To investigate the increased viability of CYLD ex7/8 B cells in vitro, the expression of the antiapoptotic gene Bcl-2 was its processed form, p52, were only slightly increased ( Fig. 7 A ) . Furthermore, we could show that the RelB protein levels were also highly increased in the cytoplasm, as well as the nucleus, of CYLD ex7/8 B cells ( Fig. 7 B ) . The elevated protein levels of TRAF2, TRAF3, p100, RelB, and I B ␣ in CYLD ex7/8 B cells likely resulted from increased protein stability rather than from increased transcriptional activity, as quantitative real-time PCR revealed no signifi cant diff erences in relative expression of these genes (Fig. S5 , available at http://www.jem.org/cgi/content/full/jem.20070318/DC1). To investigate whether the noncanonical NF-B pathway is aff ected in CYLD ex7/8 B cells, purifi ed B lymphocytes of control and CYLD ex7/8 mice were cultivated with optimal concentrations of BAFF for the indicated time points ( Fig. 7 C ) . mice results from alterations in the expression levels of proteins involved in the NF-B signaling pathway, whole-cell lysates of purifi ed B cells from three CYLD ex7/8 mutant mice and three control mice were subjected to Western blot analysis. This analysis revealed increased protein levels of TRAF2 in the CYLD mutant B cells compared with WT B cells ( Fig.  7 A ) . Additionally, the protein levels of TRAF3 and NEMO were determined, showing that TRAF3 levels were increased, whereas NEMO levels were unchanged ( Fig. 7 A ) . The levels of I B ␣ protein were markedly elevated in CYLD ex7/8 B cells, although its phosphorylation on conserved serine residues was unaltered. Most interestingly, NF B2/p100 protein levels primarily involved in the noncanonical NF-B pathway were dramatically increased, whereas the levels of ( Fig. 7 E ) . Nonstimulated CYLD ex7/8 B cells exhibited detectable NF-B activation, which was not observed in WT B cells ( Fig. 7 E ) . However, the NF-B -activating response to anti-IgM was unaltered at the diff erent time points of stimulation in CYLD ex7/8 B cells compared with WT B cells. This result suggests that the basal activity of NF-B may refl ect an increased response to a yet unknown endogenous activator.
To estimate the eff ect of the sCYLD in B cells on MAPK signaling, we performed cytometric bead assay (CBA) to determine quantitatively phosphorylated MAPKs, which can be visualized using FACS analysis. In this assay, LPS stimulation resulted in increased phosphorylation of MAPK p38 in CYLD ex7/8 B cells compared with WT B cells ( Fig. 7 F ) . Similar results were observed by Western blotting of anti-BCR -stimulated B cells ( Fig. 7 G ) . In contrast, we observed At all time points analyzed, we found increased p100 levels, but no signifi cant changes in the levels of its processed form, p52, in CYLD ex7/8 B cells when compared with controls ( Fig. 7 C ) .
To measure canonical NF-B activity in CYLD ex7/8 B cells, splenic B cells were stimulated with anti-CD40, LPS, and anti-BCR ( Fig. 7 D ) . We did not observe signifi cant differences in I B ␣ degradation upon triggering of CYLD ex7/8 and WT B cells with the aforementioned stimuli ( Fig. 7 D ) . Similarly, we did not detect changes in I B degradation and phosphorylation after anti-BCR treatment ( Fig. 7 D ) . As a direct measure of NF-B activity, we performed electrophoretic mobility shift assay (EMSA) using NF-B consensusbinding oligonucleotides with nuclear extracts from resting B cells stimulated with optimal concentrations of anti-BCR (E) EMSA was performed with extracts of B cells rested for 4 h after isolation. Cells were then activated by anti-BCR for the indicated time points before extracts were prepared, incubated with NF-B -specifi c labeled probe, and separated on native PAGE. (F) B cell lysates from CYLD ex7/8 and WT controls were stimulated with LPS for the indicated time points, and CBA was performed using beads loaded with antibodies specifi c for p-p38 and pERK1/2. (G) Western blot was performed for p-p38 and pERK from B cells of the indicated genotypes stimulated with anti-BCR for the indicated time points. Actinspecifi c antibody was used as loading control.
reduced phosphorylation of ERK1 and ERK2 upon LPS stimulation ( Fig. 7 F ) . This could be further confi rmed with Western blot analysis ( Fig. 7 G ) .
In keratinocytes isolated from CYLD ko mice, Bcl-3 associates with the NF-B proteins p52 and p50 and promotes increased transactivation of cyclin D1 compared with WT cells ( 18 ) . Although we have shown that sCYLD is able to interact with Bcl-3 and to remove K63-conjugated Ub, we were interested to see whether Bcl-3 is present in the nuclei of B cells from CYLD ex7/8 mice without activation. To this end, we prepared cytospins of CYLD ex7/8 , CYLD ex7/8;wt , CYLD ko , and WT B cells. Fig. 8 ( A and B) demonstrates that Bcl-3 was predominantly located in the nucleus, or in close proximity to the nuclei, of untreated CYLD ex7/8 B cells, whereas in WT B cells, Bcl-3 was primarily found in the cytoplasm. Calculating the percentage of B cells of the various genotypes containing nuclear Bcl-3 revealed that 60% of the CYLD ex7/8 B cells contain nuclear Bcl-3, whereas B cells from WT, CYLD ex7/8;wt , and CYLD ko exhibit 8, 3, and 2.5% of Bcl-3 in the nucleus, respectively ( Fig. 8 C ) . Furthermore, we could corroborate these results using Western blot analysis of extracts from CYLD ex7/8 mice ( Fig. 8 D ) . By quantitative realtime PCR, we could show that the increased protein levels of Bcl-3 in the B cells of the CYLD ex7/8 mice are not a result of higher Bcl-3 gene expression (Fig. S5) . Interestingly, mice that are defi cient for CYLD do not show spontaneous translocation of Bcl-3 to the nucleus. These results are reminiscent of the previously published Bcl-3 transgenic mice ( 25 ) , in which overexpression of Bcl-3 in B cells resulted in lymphadenopathy, splenomegaly, and altered immunoglobulin production, similar to what was observed in CYLD ex7/8 mice.
DISCUSSION
In this article, we report the function of a splice variant of CYLD devoid of the TRAF2 and NEMO binding sites. Expression of this shorter form of CYLD (sCYLD) with a simultaneous defi ciency of the full-length (FL) protein gave rise to a dramatic accumulation of mature B lymphocytes in all secondary lymphoid organs in vivo. This B cell accumulation is a consequence of increased survival, rather than increased proliferation, putatively resulting from aggravated Bcl-2 expression caused by various alterations in signal transduction pathways, such as NF-B and MAPK signaling. In contrast, mice that are entirely devoid of CYLD ( CYLD ko mice) do not show any abnormalities in the B cell compartment. Therefore, we reason that sCYLD has other functions in B cell homeostasis than FL-CYLD. Under physiological conditions FL-CYLD expression might be diminished, whereas the expression of sCYLD is elevated. Indeed, we detected various expression levels of both CYLD forms in diff erent tissues and cell types. Therefore, we suggest that also as essential functions for these adaptor molecules in CD40-induced class switch recombination and Ig production were reported ( 31, 32 ) . Indeed, CYLD ex7/8 B cells switch more effi ciently to IgG1, but whether this is a result of the p38 hyperactivation observed in CYLD ex7/8 B cells or a result of impaired ERK activation still needs further investigation.
Furthermore, CYLD ex7/8 B cells exhibit a signifi cant accumulation of Bcl-3 in the nucleus that cannot be explained by an inability of sCYLD to associate with Bcl-3, as we could show that sCYLD binds and removes K63-linked ubiquitin chains from Bcl-3. Western blot analysis of B lymphocytes using Bcl-3 antibody revealed aggravated Bcl-3 protein levels, whereas on the RNA level, expression of Bcl-3 was unaltered in CYLD ex7/8 B cells. Ultimately, CYLD ex7/8 mice show a very similar phenotype to mice overexpressing Bcl-3 in B lymphocytes ( 25 ) . Both transgenic mice show lymphadenopathy and splenomegaly and exhibit distorted follicles in the spleen, resulting from an enlarged B cell compartment. Further, both mouse strains showed an increase in IgG1 and decreased levels of IgM and IgG3 in the sera compared with WT mice. In addition, enhanced B cell survival, accumulation of MZ B cells, as well as increased B cell size, and the increased expression of CD21/CD23 observed in CYLD ex7/8 mice are also found in Bcl-3 transgenic mice.
The elevated expression of Bcl-2 in CYLD ex7/8 B cells may be a consequence of the dramatic overexpression of the NF-B proteins p100 and RelB, which might activate transcription of Bcl-2 in a complex with Bcl-3 upon signaling through the noncanonical NF-B pathway ( 33 ) . Thus, nuclear Bcl-3 in combination with p100 can induce the expression of Bcl-2 ( 33 ) and might account for the elevated B cell survival observed in the CYLD ex7/8 mice, as shown previously for Bcl-2 transgenic mice ( 22, 34 ) . Concomitantly, CYLD ex7/8 B cells are less dependent on BAFF signaling by a yet unsolved mechanism. This was demonstrated by ineff ective BAFF blocking by TACI-Ig. Collectively, our data suggest that the newly identifi ed splice variant sCYLD regulates B cell survival mediated through a variety of signaling disarrangements.
MATERIALS AND METHODS
Generation of CYLD mutant mice. The generation of CYLD mutant mice is described in the Supplemental materials and methods. All animal experiments were in accordance with the guidelines of the Central Animal Facility Institution of the University of Mainz.
RNA analysis. For RNA analysis, total RNA was isolated using Trizol reagent (Invitrogen) according to the manufacturer ' s instruction. The following primers were used for RT-PCR amplifi cation of mouse CYLD : P1, 5 Ј -CTCAGACCCTGGAAGTAGAA-3 Ј ; P2, 5 Ј -TTGTAATGGCCCT-GGATGCC-3 Ј . Quantitative real-time PCR of Bcl-2, p100, RelB, IkB ␣ , TRAF2, TRAF3, and Bcl-3 was performed using primers from QIAGEN, as described on their homepage (https://www1.qiagen.com/GeneGlobe/ Default.aspx).
Immunostaining of purifi ed B cells. Cytospins of purifi ed B cells were fi xed in acetone for 10 min at − 20 ° C and stained for Bcl-3 according to standard methods, using polyclonal rabbit IgG Bcl-3 antibody. All incubation steps of the staining procedure were performed at room temperature.
under normal conditions, the unique function of sCYLD can be manifested.
The CYLD-defi cient mice generated by Reiley et al. ( 26 ) demonstrate an elevated number of B lymphocyte, which is explained by a compensatory eff ect caused by the reduction in the T-lymphocyte number ( 26 ) We could demonstrate elevated protein levels of TRAF2 and TRAF3 in CYLD ex7/8 B cells, which is a consequence of impaired posttranslational modifi cation because relative expression revealed by real-time PCR was unaltered. Consistently, TRAF2 was highly ubiquitinated in CYLD ex7/8 MEFs, presumably by K63-linked Ub chains, as shown by Western blot analysis. Therefore, it is tempting to speculate that K63-ubiquitinated TRAF2 exhibit increased protein stability and possibly have impaired functionality. This is supported by the aggravated TRAF3 protein levels in CYLD ex7/8 B cells because TRAF2 was shown to be a negative regulator of TRAF3 upon stimulation with CD40 ( 28 ). B lymphocytes defi cient for TRAF2 demonstrate a phenotype similar to that of CYLD ex7/8 B cells with increased TRAF3 protein levels, but also show constitutive processing of p100 to p52, which is contrary to CYLD ex7/8 B cells ( 29 ) . In contrast, however, TRAF3-defi cient cells also display constitutive processing of p100 to p52, resulting in embryonic lethality. This phenotype can be rescued in vivo by simultaneous defi ciency of p100 ( 30 ) . Therefore, elevated TRAF3 levels should lead to increased p100 levels. Consistently, CYLD ex7/8 B cells exhibit increased p100 protein levels, but not elevated processing to p52. In addition, elevated TRAF2 and TRAF3 levels might promote MAPK p38-mediated isotype switching to IgG1, Western blot. To prepare whole-cell lysates, B cells were lysed in 1% Triton X-100 with protease inhibitors. MACS-purifi ed B cells were prepared. Protein lysates (30 g) were separated by 10% SDS-PAGE and subsequently transferred to PVDF membranes. Protein blots were probed with antibodies to phospho-I B ␣ , I B ␣ , phospho-ERK, ERK, phospho-p38, p38, p100, and Bcl-2 (all from Cell Signaling Technology), Bcl-3, NEMO, TRAF2, TRAF3, and RelB (from Santa Cruz Biotechnology), and with antibodies to actin (Sigma-Aldrich), AKT, or H2B (Cell Signaling Technology) as internal loading controls. CYLD-specifi c antibodies were prepared by immunization of rabbits with recombinant CYLD fragments. Nuclear extracts were prepared using high-salt buff er, and proteins were subjected to Western blotting. CBA was performed according to the manufacturer ' s guidelines.
Statistical analysis.
Values are presented as the means Ϯ the SEM or SD, with the number of independent experiments. Statistical diff erences were determined using the Student ' s t test.
Online supplemental material. Fig. S1 shows the targeting strategy to generate the CYLD ex7/8 mice. The cytospins were counterstained with Hoechst 33258. Cytospins were analyzed by confocal microscopy.
Histological analysis. For histological staining of B and T cells and germinal centers, frozen 6-m spleen sections were thawed, air dried, fi xed in acetone, and stained for 1 h at room temperature in a humidifi ed chamber with biotinylated rat anti-CD19 (BD Biosciences), rat anti-B220, antiCD3e, and anti-MOMA1, respectively (eBioscience), followed by horseradish peroxidase -conjugated secondary antibody and alkaline phosphatase -conjugated streptavidin.
Flow cytometry. Single-cell suspensions were prepared from the diff erent organs. Red blood cells of LN and spleen were lysed in cell suspension with tris-ammonium chloride, pH 7.2. Cells were incubated with combinations of antibodies to cell surface determinants, conjugated to PE, FITC, Cy-Cychrome, or biotin. Antibodies specifi c to the following surface markers were purchased from BD Biosciences: CD5, CD19, CD21 (7G6), CD23, HSA (CD24), CD25, CD90.2, CD43, and IgD. Anti-CD45R (B220; clone RA3-6B2) and anti-IgM (R33-24-12) were prepared in our laboratory. Biotinylated cells were visualized with streptavidin conjugated to PE or CyCychrome (BD Biosciences). Bcl-2 was visualized using anti -Bcl-2 antibody (Santa Cruz Biotechnology) and secondary donkey anti -rabbit sera conjugated to FITC (Jackson ImmunoResearch Laboratories). All samples were acquired on a FACSCalibur (BD Biosciences), and results were analyzed with CellQuest software (BD Biosciences). Absolute numbers of splenocyte subpopulations were calculated based on their percentage and the total number of splenocytes.
Immunostaining and transfection. The coding regions of murine Bcl-3, TRAF2, FL-CYLD, or sCYLD were cloned after RT-PCR using specifi c primers from the total RNA of activated B cells. PCR products were cloned in pcDNA3.1 vector (Invitrogen). HeLa cells and MEFs were transfected with the diff erent constructs or histidine-Ub (His-Ub), as described in Fig. 1 , using LipofectAmine2000 (Invitrogen). For anti -Bcl-3 or anti-TRAF2 immunoprecipitation, lysates were precleaned for 30 min at 4 ° C. The protein content was determined and compensated for equal content in all supernatants. For testing protein input, a small part of the resulting lysates was gel separated and immunoblotted (protein input), and the remaining part was used for immunoprecipitation. Immunoblots were developed with the ECL Plus reagent (GE Healthcare) according to the manufacturer ' s guidelines.
Immunization. 8-wk-old WT and CYLD ex7/8 mice were immunized intraperitoneally with 20 g of NP 28 -CCG or 100 g of KLH for TD response, or 20 g of NP-Ficoll for TI responses. On days 0, 7, 14, 21, and 28, serum was collected from peripheral blood. Circulating antibodies were measured by isotype-and antigen-specifi c ELISA. Captured antibodies were detected with enzyme-conjugated secondary antibodies.
TACI-Ig treatment. CYLD ex7/8 and control mice were treated via i.p. injection with 20 g of TACI-Ig (Alexis Biochemicals) or human IgG (Hu-Ig) twice a week for a total of 1 wk.
B cell preparation and B cell proliferation assay. Total mouse splenic B cells were purifi ed through negative depletion with CD43 beads (Miltenyi Biotech). The purity ( Ͼ 95%) was determined by fl ow cytometry. For in vitro proliferation studies, B cells were labeled with CFSE, and 2 ϫ 10 5 cells/ well were incubated in RPMI medium plus 10% FCS or untreated or treated with 5 g/ml anti-CD40, 5 g/ml anti-IgM, 2 g/ml LPS, and 5 ng/ml LPS plus IL-4 with and without 100 ng/ml BAFF for 4 d.
Measurement of TNF ␣ -induced cell death. MEFs (10 6 per well) were plated onto 6-well plates and cultured for 24 h in DME containing 10% FCS. Subsequently, the cells were stimulated with either 10 ng/ml TNF ␣ with and without 300 ng/ml cycloheximide. Triplicate samples of TNF ␣ -induced cell death were measured by FACS analysis using Topro3 and Annexin V.
